[EN] PHARMACEUTICAL SALT FORMS OF AN INHIBITOR OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) [FR] FORMES DE SELS PHARMACEUTIQUES D'UN INHIBITEUR D'UNE OXYDASE D'AMINE SENSIBLE AUX SEMI-CARBAZIDES (SSAO)
The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
[EN] CRYSTALLINE COMPOUND AS SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME INHIBITOR<br/>[FR] COMPOSÉ CRISTALLIN UTILISÉ EN TANT QU'INHIBITEUR D'ENZYME AMINE OXYDASE SENSIBLE AUX SEMICARBAZIDES (SSAO)
申请人:PROXIMAGEN LTD
公开号:WO2016170352A1
公开(公告)日:2016-10-27
A specific crystalline mesylate salt form of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate, and the use of the same in medicine. (Formula (I))
[EN] PROCESS FOR THE PREPARATION OF (3S,4S)-TETRAHYDROFURAN-3-YL 4-ISOPROPYL-6,7-DIHYDRO-3H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-CARBOXYLATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE (3S,4S)-TÉTRAHYDROFURAN-3-YL 4-ISOPROPYL -6,7-DIHYDRO -3 H-IMIDAZO [4,5-C] PYRIDINE -5 (4H)-CARBOXYLATE
申请人:PROXIMAGEN LTD
公开号:WO2018078363A1
公开(公告)日:2018-05-03
The invention relates to an improved process for the synthesis of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
[EN] TREATMENT OF PAIN<br/>[FR] TRAITEMENT DE LA DOULEUR
申请人:PROXIMAGEN LTD
公开号:WO2016170353A1
公开(公告)日:2016-10-27
(3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.
The present invention relates to compounds of formula (I),
and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.